Timing of anti-PD-L1 antibody initiation affects efficacy/toxicity of CD19 CAR T-cell therapy for large B-cell lymphoma.

"Conflict-of-interest disclosure: A.V.H. has received research funding from Juno Therapeutics, a Bristol Myers Squibb company, and Nektar Therapeutics, and honoraria from Bristol Myers Squibb and Novartis. E.L.K. has received research funding from Juno Therapeutics, a Bristol Myers Squibb company. S.F. reports grants from Bristol Myers Squibb and other support in the form of pending equity from Link Immunotherapeutics outside of the submitted work; has issued patents for PCT/US2021/025255 and PCT/US2021/025248d; and a patent for PCT/US2021/025260 issued, licensed, and with royalties paid from Bristol Myers Squibb. J.G. has received research funding from Sobi, Juno Therapeutics, a Bristol Myers Squibb company, Celgene, and Angiocrine Bioscience, and has received honoraria/consulting fees from Sobi, Legend Biotech, Janssen, Kite Pharma, a Gilead company, and MorphoSys. C.C.S.Y. has received research funding from OBI Pharma, Lonza, Sensei, Signal One, and Pfizer, and serves on scientific advisory boards for Twinstrand Biosciences, AbbVie, Eli Lilly, and Loxo. R.D.C. has received research funding from Amgen, Incyte, Kite Pharma, a Gilead company, Pfizer, Servier, and Vanda Pharmaceuticals; has received honoraria/consulting fees from Amgen, Jazz, Kite/Gilead, and Pfizer; serves on a data and safety monitoring board for Pepromene Bio and on an independent response review committee for Autolus; and his spouse has been employed by and owned stock in Seagen. A.G.C. has received research funding from Juno Therapeutics, a Bristol Myers Squibb company. D.J.G. has received research funding from, has served as an adviser for, and has received royalties from Juno Therapeutics, a Bristol Myers Squibb company; has served as an adviser and received research funding from Seattle Genetics; has served as an adviser to GlaxoSmithKline, Celgene, Janssen Biotech, and Legend Biotech; and has received research funding from SpringWorks Therapeutics, Sanofi, and Cellectar Biosciences. M.S. has received research funding from Mustang Bio, Bristol Myers Squibb, Pharmacyclics, Genentech, AbbVie, TG Therapeutics, BeiGene, AstraZeneca, Genmab, MorphoSys/Incyte, and Vincerx; has served as a consultant for AbbVie, Genentech, AstraZeneca, Pharmacyclics, Beigene, Bristol Myers Squibb, MorphoSys/Incyte, Kite, Eli Lilly, Genmab, Mustang Bio, Regeneron, ADC Therapeutics, Janssen, Fate Therapeutics, and MEI Pharma; and his spouse is an employee of Bristol Myers Squibb. B.G.T. has received research funding from Mustang Bio and Juno Therapeutics, a Bristol Myers Squibb company; serves on scientific advisory boards for Mustang Bio and Proteios Technology; and has the right to receive royalties from Fred Hutch as an inventor on licensed patents. S.R.R. is a cofounder and adviser to Lyell Immunopharma and has received research funding from and intellectual property licensed to Lyell Immunopharma; was a cofounder of Juno Therapeutics, a Bristol Myers Squibb company; is an inventor of patents licensed to Juno Therapeutics; and served as an adviser to Juno Therapeutics and Adaptive Biotechnologies. D.G.M. has received research funding from Juno Therapeutics, a Bristol Myers Squibb company, Celgene, and Kite Pharma, a Gilead company; has served on ad hoc advisory board meetings for Amgen, Bristol Myers Squibb, Genentech, Gilead, Incyte, Janssen, Legend Biotech, Mustang Bio, MorphoSys, Novartis, Pharmacyclics, and Umoja; has rights to receive royalties from Fred Hutch for patents licensed to Juno Therapeutics; and serves on scientific advisory board with stock options and compensations for A2 Biotherapeutics and Navan Technologies. C.J.T. has received research funding from Juno Therapeutics, a Bristol Myers Squibb company, NanoString Technologies, and Nektar Therapeutics; serves on scientific advisory boards for Caribou Biosciences, T-CURX, Myeloid Therapeutics, ArsenalBio, and Cargo Therapeutics; serves on a data and safety monitoring board for Kyverna; has served on ad hoc advisory board meetings (last 12 months) for Legend Biotech, Nektar Therapeutics, and Syncopation Life Sciences; performs consulting for Century Therapeutics, Orna Therapetuics, and IGM Biosciences; has stock options in Eureka Therapeutics, Caribou Biosciences, Myeloid Therapeutics, Cargo Therapeutics, and ArsenalBio; and has the right to receive payments from Fred Hutch as an inventor on licensed patents. The remaining authors have declared no competing financial interests."

"This work was supported by 10.13039/100000002National Institutes of Health (NIH), 10.13039/100000054National Cancer Institute grants R01 CA136551 and P30 CA15704, 10.13039/100000002NIH 10.13039/100000062National Institute of Diabetes and Digestive and Kidney Diseases grant P30 DK56465, 10.13039/100000002NIH 10.13039/100000050National Heart, Lung, and Blood Institute funded National Gene Vector Biorepository at 10.13039/100006733Indiana University (contract no. 75N92019D00018), Life Science Discovery Fund, the Bezos family, Fred Hutch Immunotherapy Integrated Research Center, Juno Therapeutics, a Bristol Myers Squibb company, and AstraZeneca."